ClinicalTrials.gg
Not yet recruitingNCT07046013Updated Jul 1, 2025

Level of Serum Lactate Dehydrogenase in Immune Thrombocytopenia

An observational study in Immune Thrombocytopenia (ITP), sponsored by Sohag University. Not yet recruiting. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Sohag University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
40
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University — 6 open to participants now, 6 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Sohag University.

Started
2025
with 2 others
Observational
6 of 11
4 open now
Registered
8th of 11
by date

Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, or all of them as a file.
02

Study summary

Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia

Read the detailed description

Immune thrombocytopenia is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation.

Lactate dehydrogenase is a group of oxidoreductase isoenzymes catalyzing the reversible reaction between pyruvate and lactate.

The LDH was found to be moderately high in patients with immune thrombocytopenia at the time of diagnosis.

03

Conditions studied

  • Immune Thrombocytopenia (ITP)
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Sample collected from people newly diagnosed Immune thrombocytopenia at the time of diagnosis.

Laboratory investigations: LDH_CBC_ESR_Bone marrow aspirate

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Thrombocytopenia patients at the time of diagnosis.

Exclusion criteria

Exclusion Criteria:

  • bone fractures _ bone diseases_
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testLactate dehydrogenase

    It's elevation at the time of diagnosis

06

What researchers measure

Primary outcomes

  1. Relation between serum lactate dehydrogenase and immune thrombocytopenia

    Time frame: About 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Jun 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2025
First posted
Jul 1, 2025
StartEst.
Aug 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046013
Lead sponsor
Sohag University
Responsible party
Shimaa Mahmoud Fahmy (Principal investigator, Sohag University) — Principal investigator
First posted
Jul 1, 2025
Start date
Aug 2025 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 1, 2025

Study contacts

Shaimaa Mahmoud Fahmy, Resident doctor
Contact
shaimaa333mahmoud333@gmail.com
01149586292
Hassnaa Ahmed Abo elwafa, Prof.Dr
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion